Clinical trial · no report yet · Phase 3
ZUMA-22
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
- NCT05371093 ↗
- Active not recruiting
- Kite, A Gilead Company
- 21 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 14 | |
| Podcasts | 6 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Relapsed/Refractory Follicular Lymphoma
- Interventions
- Axicabtagene Ciloleucel; Cyclophosphamide; Fludarabine; Lenalidomide; Rituximab; Doxorubicin; Vincristine; Prednisone; Bendamustine
- Arms
- Axicabtagene Ciloleucel · Experimental
- Standard of Care Therapy · Active comparator
- Enrollment
- 231
- Primary outcomes
- Progression-free Survival (PFS) as Assessed by Blinded Central Assessment per Lugano Classification
- Sponsor
- Kite, A Gilead Company
- Start
- Sep 22, 2022
- Primary completion
- Oct 2030 (estimated)
- Results posted
- No
- Registry record
- NCT05371093 · updated Oct 15, 2025